Influence of p53 and bcl-2 on proliferative activity and treatment outcome in head and neck cancer patients

Oral Oncology

Volumn 36, Issue 1, 2000, Pages 54-60

  Dijkema, I M ^a   Struikmans, H ^a   Dullens, H F J ^a   Kal, H B ^a   Van Der Tweel, I ^b   Battermann, J J ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b Centre for Biostatistics   (Netherlands)

Author keywords

bcl 2; Cell proliferation; Head and neck tumors; p53; Prognosis

Indexed keywords

BIOLOGICAL MARKER; PROTEIN BCL 2; PROTEIN P53;

ADULT; AGED; ARTICLE; CELL PROLIFERATION; CLINICAL TRIAL; FEMALE; FLOW CYTOMETRY; HEAD AND NECK CANCER; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RADIOSENSITIVITY; RECURRENCE RISK; SQUAMOUS CELL CARCINOMA; SURVIVAL TIME; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, SQUAMOUS CELL; CELL DIVISION; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; MUTATION; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-BCL-2; TREATMENT OUTCOME; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0033990728     PISSN: 13688375     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1368-8375(99)00051-2     Document Type: Article

References (35)

1. Gasparini G., Bevilacqua P., Bonoldi E.et al. Predictive and prognostic markers in a series of patients with head and neck squamous cell invasive carcinoma treated with concurrent chemoradiation therapy. Clinical Cancer Research. 1:1995;1375-1383.
2. Struikmans H., Rutgers D.H., Hordijk G.J.et al. Prognostic significance of cell proliferation markers and DNA-ploidy in head and neck tumors. International Journal of Radiation Oncology, Biology, Physics. 40:1998;27-34.
3. Wilson G.D., Grover R., Richman P.I.et al. Bcl-2 expression correlates with favourable outcome in head and neck cancer treated by accelerated radiotherapy. Anticancer Research. 16:1996;2403-2408.
4. Nordsmark M., Overgaard M., Overgaard J. Pretreatment oxygenation predicts radiation response in advanced squamous cell carcinoma of the head and neck. Radiotherapy and Oncology. 41:1996;31-39.
5. Horiot J.C., Bontemps P., van den Bogaert W.et al. Accelerated fractionation (AF) compared to conventional fractionation (CF) improves loco-regional control in the radio-therapy of advanced head and neck cancers: results of the EORTC 22851 randomized trial. Radiotherapy and Oncology. 44:1997;111-121.
6. Withers H.R., Taylor J.M., Maciejeski B. The hazard of accelerated tumor clonogen repopulation during radiotherapy. Acta Oncology. 27:1988;131-146.
7. Begg A.C., Haustermans K., Hart A.A.M.et al. The value of pretreatment cell kinetic parameters as predictors for radiotherapy outcome in head and neck cancer: a multicenter analysis. Radiotherapy and Oncology. 50:1999;13-23.
8. Friedman M.et al. Prognostic significance of bcl-2 expression in localized squamous cell carcinoma of the head and neck. Annals of Otology, Rhinology and Laryngology. 106:1997;445-450.
9. Wilson G.D., Richman P.I., Dische S.et al. P53 status of head and neck cancer: relation to biological characteristics and outcome in radiotherapy. British Journal of Cancer. 71:1995;1248-1252.
10. Kerr J.F., Winterford C.M., Harmon B.V. Apoptosis: its significance in cancer and cancer therapy. Cancer. 73:1994;2013-2026.
11. Bristow R.G., Benchimol S., Hill R.P. The p53 gene as a modifier of intrinsic radiosensitivity: implications for radiotherapy. Radiotherapy and Oncology. 40:1996;197-223.
12. Goodger N.M., Gannon J., Hunt T., Morgan P.R. Cell cycle regulatory proteins - an overview with relevance to oral cancer. Oral Oncology. 33:1997;61-73.
13. Yarnold J. Molecular aspects of cellular responses to radiotherapy. Radiotherapy and Oncology. 44:1997;1-7.
14. Hill M.E., MacLennan K.A., Cunningham D.C.et al. Prognostic significance of bcl-2 expression and bcl-2 major breakpoint region rearrangement in diffuse large cell non-Hodgkin's lymphoma: a British National Lymphoma Investigation study. Blood. 88:1996;1046-1051.
15. Silvestrini R., Veneroni S., Daidone M.G.et al. The bcl-2 protein: a prognostic indicator strongly related to p53 protein in lymph node-negative breast cancer patients. Journal of the National Cancer Institute. 86:1994;499-504.
16. Watson A.J., Merrit A.J., Lones L.S.et al. Evidence for reciprocity of bcl-2 and p53 expression in human clorectal adenomas and carcinomas. British Journal of Cancer. 74:1996;889-895.
17. Hale A.J., Smith C.A., Sutherland L.C.et al. Apoptosis: molecular regulation of cell death. European Journal of Biochemistry. 236:1996;1-26.
18. Borner C. Diminished cell proliferation associated with the death-protective activity of bcl-2. The Journal of Biological Chemistry. 271:1996;12695-12698.
19. Mazel S., Burtrum D., Petrie H.T. Regulation of cell division cycle progression by bcl-2 expression: a potential mechanism for inhibition of programmed cell death. Journal of Experimental Medicine. 183:1996;2219-2226.
20. Salo A., Servomaa K., Kiuru A.et al. The bcl-2 gene status of human head and neck cancer cell lines. Acta Otolaryngologica (Stockholm). 529(Suppl.):1997;233-236.
21. Pellegata N.S., Antoniono R.J., Redpath J.L.et al. DNA damage and p53-mediated cell cycle arrest: a reevaluation. Proceedings of the National Academy of Sciences USA. 93:1996;15209-15214.
22. Servomaa K., Kiuri A., Grénman R.et al. P53 mutations associated with increased sensitivity to ionizing radiation in human head and neck cancer cell lines. Cell Proliferation. 29:1996;219-230.
23. Tan L.K., Ogden G.R. P53 over-expression in laryngeal carcinoma is not predictive of response to radiotherapy. Oral Oncology. 33:1997;177-181.
24. Gallo O., Boddi V., Calzolari A.et al. Bcl-2 protein expression correlates with recurrence and survival in early stage head and neck cancer treated by radiotherapy. Clinical Cancer Research. 2:1996;261-267.
25. Veneroni S., Silvestrini R., Costa A.et al. Biological indicators of survival in patients treated by surgery for squamous cell carcinoma of the oral cavity and oropharynx. Oral Oncology. 33:1997;408-413.
26. Bourish J., Bosq J., Wilson G.D.et al. Correlation between p53 gene expression and tumor-cell proliferation in oropharyngeal cancer. International Journal of Cancer. 57:1994;458-462.
27. Schutte B., Reynderd M.M., van Assche C.L.et al. An improved method for the immunocytochemical detection of bromodeoxyuridine labelled nuclei using flow cytometry. Cytometry. 8:1987;372-376.
28. Van der Linden P.M. An iterative method of analysis for DNA histograms. Acta Pathologica et Microbiologica Scandinavica. 274(Suppl.):1981;133-137.
29. Beck H.P. Evaluation of flow cytometric data of human tumours. Correction procedures for background and cell aggregations. Cell Tissue Kinetics. 13:1980;173-181.
30. Begg A.C., McNally N.J., Shrieve D.C. A method to measure the duration of the DNA synthesis and the potential volume doubling time from a single sample. Cytometry. 6:1985;620-626.
31. Jin Y., Kayser S., Kemp B.L.et al. The prognostic significance of the biomarkers p21, p53, and bcl-2 in laryngeal squamous cell carcinoma. Cancer. 82:1998;2159-2165.
32. Narayana A., Vaughan A.T., Gunaratne S.et al. Is p53 an independent prognostic factor in patients with laryngeal carcinoma? Cancer. 82:1998;286-291.
33. Kropveld A, Leppers FG, Scheidel CC et al. Beyond the p53 core domain: towards 100% concordance between immunohistochemical findings and gene mutations. In: Kropveld A, editor. P53 in Diagnosis and Treatment of Head and Neck Cancer. Utrecht, 1998. p. 123-136.
34. Cayrol C., Knibiehler M., Ducommun B. P21 binding to PCNA causes G1 and G2 cell cycle arrest in p53-deficient cells. Oncogene. 16:1998;311-320.
35. Pietenpol J.A., Papadopoulos N., Markowitz S.et al. Paradoxical inhibition of solid tumor cell growth by bcl2. Cancer Research. 54:1994;3714-3717.